

18 September 2017

#### **ANO Investor Presentation Amended**

Please note we apologise but have made an amendment to page 2 of the Investor Presentation and have released a new version.

Please find attached the amended Advanced Nano Technologies Investor Presentation – September 2017.

Geoff Acton (B.Com CA) Managing Director


A: 1821 Ipswich Rd Rocklea Qld 4106 | PO Box: PO Box 229, Sherwood Qld 4075 T: +61 (7) 3274 0772 | www.antaria.com | ABN: 54 079 845 855



# ANO Investor Presentation September 2017

#### **ZinClear® Photostable Protection**

Sunscreen performance after 3 hours in Australian sun (average UV load), measured in Perth, Western Australia






"23 various skin cancer procedures -For me it's not just business, it's PERSONAL" Managing Director Geoff Acton


1

## **ANO Geographical Sales in AUD**




- Increase in ZinClear revenue of 14.32% despite 3 months of no sales due to a forced change in precursor suppliers.
- All ZinClear IM products based around new precursor and external testing results are better than previous precursor.

# **Total Annual Sales Revenue by Product Category (\$)**




- Total sales increase of 16.17%.
- In 2014, Merck purchased far more product than their sales which meant Merck had significant stock holdings in FY15 and FY16.
- The new agreement will see more consistent purchase volumes of Alusion by Merck with further sales increases expected in FY18.
- The new decanter (part of the qualified audit opinion on assets by the auditor) is being installed which will reduce bottlenecks in production.

# ANO Total Operating Costs (Including Wages) (\$)




- Further reductions expected once the transition to 112 Radium Street is completed and 108 Radium Street closes of approximately \$250,000 annualised.
- Rent reduction of 30% is being negotiated at 112 Radium Street.
- The contract manufacturing arrangement in the US combined with new precursor supply arrangements will result in further costs savings.
- The combined manufacturing facility in Australia will also lead to significant cost savings in FY18.

#### Wages as a % of Sales Revenue




• No Bonuses or incentives were paid to any Directors or Managers in FY17.

#### **Travel Expense as a % of Sales Revenue**



- Have increased the distributor and chemist network without significant travel.
- Travel limited to inspecting new manufacturing facilities and signing significant agreements with customers, suppliers and manufacturers.
- New approach involving local distributors has replaced travel to major international trade shows.

### **Number of Distributors and Resellers**



#### **GLOBAL DISTRIBUTION NETWORK**

- Bregaglio Italy
- Connell Brothers India India
- Connell Brothers Malaysia Malaysia
- Deveraux Specialities LLC. USA
- ENS Beauty Group South Korea
- Heterochem UK / Ireland


- Manuchar Indonesia / Philippines / Thailand
- Neochem Gmbh Germany / Austria
- Pachem Distribution Canada
- Para Chemie Sina Iran
- Pure Ingredients New Zealand

#### RESELLERS

- Quimica Suiza Industrial Peru
- Y.S. Ashkenazi Agencies Israel
- Gadot Group Israel


7

## ANO R&D Costs and Number of Formulations and Products Being Developed




- 32 end formulations in various stages of development including sunscreens, lipsticks, after shave lotions, day repair creams, foundations, anti acne creams, and facial masks.
- 4 different plastic film compositions, ceria (as a catalyst for clean coal burning), 2 battery compositions, and ZNO material for 3D printing in ceramics (these are highly speculative).
- In addition we have completed full testing on new precursor suppliers and a full review of all prior research undertaken for possible patent and commercial opportunities.

## Number of Chemists Supporting our Products




- The unique nature of our product and difficulties in product development requires barriers to substitution
- ANO is investing in this product formulation and R&D to support our small customers who do not have the resources to develop end formulations.
- Looking forward to releasing our own ZinXation range of products in 2018/2019
- ZinXation will be much more valued by the current Board than Invisible Zinc was by the original board who sold the brand (now worth > \$40 million) without agreements and our active ingredient being used in the products.

#### **Number of New Patents Developed**




 Patent renewals are not included as the process is ongoing and the number of renewals will vary depending on expiry dates.

# ANO Trading Result (Excluding R&D Income)



- Total losses accumulated \$37million over 14 years
- The board would love to see more rapid improvement, in the results, however the inertia encountered in FY17 was far greater than we expected.
- The US distributor has signed a 3 year agreement for sales and distribution in the US and Mexico with parties agreeing to a 55% increase in sales in calendar 2018.
- While the board is keen to see more rapid improvement in the financial results, the inertia and entrenched practices in the Perth facility were far greater than expected.

### **ANO Share Price**




11

# **Overview UV Absorbers Portfolio**


	PRODUCT NAME	INCI	RANGE OF ABSORPTION	ACTIVE	Ac (nm)	VISCOSITY	NATURAL
ZinClear IM <sup>®</sup> Optimized for Transparency with Index Match Technology	ZinClear IM®50JJ	Zinc Oxide (and) Simmondsia Chinensis (Jojoba) Seed oil (and) Glyceryl Isostearate (and) Polyhydroxystearic Acid	UVA & UVB	50	Broad spectrum 370nm	Pourable	ECOCERT RWWAREAL COSMETICS
	ZinClear IM®50CCT	Zinc Oxide (and) Caprylic/Capric Triglyceride (and) Polyhydroxystearic Acid (and) Glyceryl Isostearate	UVA & UVB	50	Broad spectrum 370nm	Pourable	ECOCERT RWW MATERIAL COSMETICS
Optimized for	ZinClear IM®50AB	Zinc Oxide (and) C12-15 Alkyl Benzoate (and) Polyhydroxystearic Acid (and) Isostearic Acid	UVA & UVB	50	Broad spectrum 370nm	Pourable	
	ZinClear IM®55L7	Zinc Oxide (and) Neopentyl Glycol Diheptanoate (and) Glyceryl Isostearate (and) Polyhydroxystearic Acid (and) Cetyl PEG/PPG-10/1 Dimethicone	UVA & UVB	55	Broad spectrum 370nm	Pourable	
ZinClear XP <sup>TM</sup> 370nm Critical Wavelength	ZinClear XP™ 65COCO	Zinc Oxide (and) Coco-Caprylate/ Caprate (and) Polyglyceryl-3 Polyricinoleate (and) Isostearic Acid	UVA & UVB	65	Broad spectrum > 370nm	Pourable	COSMETICS
<b>Z</b> >370nm	ZinClear XP™	Zinc Oxide	UVA & UVB	100	Broad spectrum > 370nm	Free flowing powder	Approved by ECOCERT RAW MATERIAL COSMETICS

# ZinClear® Photostable Protection


Sunscreen performance after 3 hours in Australian sun (average UV load), measured in Perth, Western Australia



## **ZinClear® Absorbance of UVB and UVA**



### **ZinClear IM® is Optimized for Transparency**



#### **Disclamer**

Management of Advanced Nano Technologies Ltd (ABN 54 079 845 855) and its subsidiaries (collectively 'ANO') has made every effort to ensure the accuracy of information contained in this presentation.

The presentation has been prepared based on information available prior to the date of this presentation.

No responsibility or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation.

To the maximum extent permitted by law, none of Advanced Nano Technologies, its related bodies corporate or any of its directors, employees, agents or advisers accept any liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability arising from fault or negligence on the part of Advanced Nano Technologies, its related bodies corporate or any of its directors, employees, agents or advisers.

The material contained in this presentation is for information purposes only and does not constitute financial product advice.

The information contained in this presentation has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. Before making any investment decision, you should consider, with or without the assistance of a financial adviser, whether an investment is appropriate in light of your particular investment needs, objectives and financial circumstances. Nothing in this presentation is a promise or representation as to the future.

Statements or assumptions in this presentation as to future matters may prove to be incorrect and the differences may be material.